# A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

> **NCT05421858** · PHASE3 · RECRUITING · sponsor: **Basilea Pharmaceutica** · enrollment: 450 (estimated)

## Conditions studied

- Candidemia
- Candidiasis, Invasive

## Interventions

- **DRUG:** Fosmanogepix
- **DRUG:** Fosmanogepix
- **DRUG:** Caspofungin
- **DRUG:** Fluconazole
- **DRUG:** Placebo
- **DRUG:** Placebo
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05421858
- **Lead sponsor:** Basilea Pharmaceutica
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-11
- **Primary completion:** 2028-01-30
- **Final completion:** 2028-01-30
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2026-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05421858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05421858, "A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT05421858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*